A Metabolomic Analysis of Sensitivity and Specificity of 23 Previously Proposed Biomarkers for Renal Transporter‐Mediated Drug‐Drug Interactions

Endogenous biomarkers are discussed as tools for detection of drug‐drug interactions (DDIs) mediated by renal transport proteins, such as organic cation transporter 2 (OCT2), multidrug and toxin extrusion proteins (MATE1 and MATE2‐K) and organic anion transporters (OAT1 and OAT3). Whereas sensitivity of some endogenous biomarkers against at least one clinical transporter inhibitor has frequently been shown, intra‐study comparisons of the extent of effects of inhibitors on different biomarkers are frequently lacking. Moreover, in vivo specificity of such discussed biomarkers has frequently not been studied. We therefore investigated changes of 10 previously described putative biomarkers for inhibition of OCT2/MATEs, as well as 15 previously described putative biomarkers for OATs in human plasma and urine samples of healthy volunteers in response to treatment with 4 inhibitors of transport proteins [verapamil (P‐glycoprotein), rifampin (organic anion transporting polypeptides), cimetidine (OCT2/MATEs), and probenecid (OATs)]. Two of the putative biomarkers had been suggested for both OCT2/MATEs and OATs. All substances were unequivocally identified in an untargeted metabolomics assay. The OCT2/MATE biomarkers choline and trimethylamine N‐oxide were both sensitive and specific (median log2‐fold changes −1.18 in estimated renal elimination and −0.85 in urinary excretion, respectively). For renal OATs, indoleacetyl glutamine and indoleacetic acid (median log2‐fold changes −3.77 and −2.85 in estimated renal elimination, respectively) were the candidates for sensitive and specific biomarkers with the most extensive change, followed by taurine, indolelactic acid, and hypoxanthine. This comprehensive study adds further knowledge on sensitivity and specificity of 23 previously described biomarkers of renal OCT2/MATE‐ and OAT‐mediated DDIs.

[1]  F. Müller,et al.  N1‐Methylnicotinamide as Biomarker for MATE‐Mediated Renal Drug–Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid , 2023, Clinical pharmacology and therapeutics.

[2]  R. Masereeuw.  The Dual Roles of Protein-Bound Solutes as Toxins and Signaling Molecules in Uremia , 2022, Toxins.

[3]  S. Nigam,et al.  Blockade of Organic Anion Transport in Humans After Treatment With the Drug Probenecid Leads to Major Metabolic Alterations in Plasma and Urine , 2022, Clinical pharmacology and therapeutics.

[4]  S. Liabeuf,et al.  The Interplay between Uremic Toxins and Albumin, Membrane Transporters and Drug Interaction , 2022, Toxins.

[5]  R. Greiner,et al.  HMDB 5.0: the Human Metabolome Database for 2022 , 2021, Nucleic Acids Res..

[6]  A. Sparreboom,et al.  Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation , 2021, Molecules.

[7]  U. Murty,et al.  Transporter-mediated drug–drug interactions: advancement in models, analytical tools, and regulatory perspective , 2021, Drug metabolism reviews.

[8]  A. Galetin,et al.  Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug–Drug Interactions , 2021, Clinical Pharmacokinetics.

[9]  Sophia L. Samodelov,et al.  Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology , 2020, International journal of molecular sciences.

[10]  K. Maeda,et al.  Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development. , 2020, Drug metabolism and pharmacokinetics.

[11]  A. D. Rodrigues,et al.  Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein‐Mediated Drug‐Drug Interactions in Healthy Volunteers , 2020, Clinical pharmacology and therapeutics.

[12]  F. Müller,et al.  Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine , 2020, Clinical Pharmacokinetics.

[13]  W. Lieb,et al.  Trimethylamine-N-oxide (TMAO) determined by LC-MS/MS: distribution and correlates in the population-based PopGen cohort , 2020, Clinical chemistry and laboratory medicine.

[14]  H. Koepsell.  Organic Cation Transporters in Health and Disease , 2020, Pharmacological Reviews.

[15]  M. Krempf,et al.  Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease: Contribution of Decreased Glomerular Filtration Rate , 2019, Toxins.

[16]  K. Maeda,et al.  Elucidation of N1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters , 2019, Drug Metabolism and Disposition.

[17]  M. Fromm,et al.  Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions , 2019, Clinical pharmacology and therapeutics.

[18]  K. Giacomini,et al.  The International Transporter Consortium: Summarizing Advances in the Role of Transporters in Drug Development , 2018, Clinical pharmacology and therapeutics.

[19]  Yuichi Sugiyama,et al.  Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium , 2018, Clinical pharmacology and therapeutics.

[20]  H. Moch,et al.  Fluorocholine Transport Mediated by the Organic Cation Transporter 2 (OCT2, SLC22A2): Implication for Imaging of Kidney Tumors , 2018, Drug Metabolism and Disposition.

[21]  M. Fromm,et al.  Contribution of multidrug and toxin extrusion protein 1 (MATE1) to renal secretion of trimethylamine-N-oxide (TMAO) , 2018, Scientific Reports.

[22]  F. Müller,et al.  Biomarkers for In Vivo Assessment of Transporter Function , 2018, Pharmacological Reviews.

[23]  Xiaokui Huo,et al.  Renal organic anion transporters in drug–drug interactions and diseases , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  K. Maeda,et al.  Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide. , 2017, Journal of pharmaceutical sciences.

[25]  C. Cho,et al.  The metabolic fate of isotopically labeled trimethylamine-N-oxide (TMAO) in humans. , 2017, The Journal of nutritional biochemistry.

[26]  R. Hegele,et al.  Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. , 2017, Molecular pharmaceutics.

[27]  K. Maeda,et al.  Investigation of Endogenous Compounds Applicable to Drug–Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans , 2016, Drug Metabolism and Disposition.

[28]  O. Mortensen,et al.  Physiological role of taurine – from organism to organelle , 2015, Acta physiologica.

[29]  F. Müller,et al.  N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin–trimethoprim interaction , 2014, European Journal of Clinical Pharmacology.

[30]  Emma L. Schymanski,et al.  Identifying small molecules via high resolution mass spectrometry: communicating confidence. , 2014, Environmental science & technology.

[31]  K. Brouwer,et al.  In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development , 2013, Clinical pharmacology and therapeutics.

[32]  L Zhang,et al.  Transporter Studies in Drug Development: Experience to Date and Follow‐Up on Decision Trees From the International Transporter Consortium , 2013, Clinical pharmacology and therapeutics.

[33]  H. Kusuhara,et al.  N‐Methylnicotinamide Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving Multidrug and Toxin Extrusions (MATE1 and MATE2‐K) , 2012, Clinical pharmacology and therapeutics.

[34]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[35]  Jian Yan,et al.  Trimethylamine‐N‐oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: A randomized controlled trial , 2017, Molecular nutrition & food research.

[36]  H. Kusuhara,et al.  Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins , 2013, Pharmaceutical Research.

[37]  Guideline on the Investigation of Drug Interactions , 2010 .

[38]  H. Kusuhara,et al.  Characterization of uremic toxin transport by organic anion transporters in the kidney. , 2004, Kidney international.